Anders Wimo

Summary

Country: Sweden

Publications

  1. ncbi request reprint Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease
    Anders Wimo
    Division of Geriatric Epidemiology Sector of Health Economy, Neurotec, Karolinska Institute, Huddinge, Sweden
    Pharmacoeconomics 21:327-40. 2003
  2. ncbi request reprint Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease
    Bengt Winblad
    Karolinska Institutet Alzheimer Research Center, Huddinge, Sweden
    Int J Geriatr Psychiatry 22:485-91. 2007
  3. doi request reprint Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients
    Anders Gustavsson
    Alzheimer s Disease Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden
    Alzheimers Dement 7:318-27. 2011
  4. ncbi request reprint Validity and reliability of assessments of time. Comparisons of direct observations and estimates of time by the use of the resource utilization in dementia (RUD)-instrument
    Anders Wimo
    Aging Research Center ARC, Division of Geriatric Epidemiology and Medicine, Neurotec, Karolinska Institutet, Huddinge Hospital, B84, S 141 86 Stockholm, Sweden
    Arch Gerontol Geriatr 44:71-81. 2007
  5. ncbi request reprint Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL
    Linus Jönsson
    Neurotec, Section for Geriatric Epidemiology, Karolinska Institutet, Stockholm, Sweden
    Alzheimer Dis Assoc Disord 20:49-55. 2006
  6. ncbi request reprint More illness and less disease? A 20-year perspective on chronic disease and medication
    Bertil Hagstrom
    Department of Primary Health Care, Goteborg University, Goteborg, Sweden
    Scand J Public Health 34:584-8. 2006
  7. ncbi request reprint Societal burden and economics of vascular dementia: preliminary results from a Swedish-population-based study
    Anders Wimo
    Neurotec, Division of Geriatric Epidemiology, Karolinska Institutet, Stockholm, Sweden
    Int Psychogeriatr 15:251-6. 2003
  8. ncbi request reprint Impact of donepezil treatment for Alzheimer's disease on caregiver time
    Anders Wimo
    Karolinska Institutet, Huddinge, Sweden
    Curr Med Res Opin 20:1221-5. 2004
  9. ncbi request reprint The use of angiotensin-converting enzyme inhibitors and other drugs with cardiovascular effects by non-demented and demented elderly with a clinical diagnosis of heart failure. A population-based study of the very old
    Inga Klarin
    Aging Research Center, Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Gavlegatan 16, 113 30, Stockholm, Sweden
    Eur J Clin Pharmacol 62:555-62. 2006
  10. ncbi request reprint The association of inappropriate drug use with hospitalisation and mortality: a population-based study of the very old
    Inga Klarin
    Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Stockholm, Sweden
    Drugs Aging 22:69-82. 2005

Detail Information

Publications24

  1. ncbi request reprint Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease
    Anders Wimo
    Division of Geriatric Epidemiology Sector of Health Economy, Neurotec, Karolinska Institute, Huddinge, Sweden
    Pharmacoeconomics 21:327-40. 2003
    ..Alzheimer's disease (AD) is a devastating illness that causes enormous emotional stress to affected families and is associated with substantial medical and nonmedical costs...
  2. ncbi request reprint Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease
    Bengt Winblad
    Karolinska Institutet Alzheimer Research Center, Huddinge, Sweden
    Int J Geriatr Psychiatry 22:485-91. 2007
    ..Transdermal patches may offer advantages over conventional oral formulations...
  3. doi request reprint Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients
    Anders Gustavsson
    Alzheimer s Disease Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden
    Alzheimers Dement 7:318-27. 2011
    ..We aimed to identify what measures of disease severity are the most important predictors of societal costs of care and whether their relationship differs across countries...
  4. ncbi request reprint Validity and reliability of assessments of time. Comparisons of direct observations and estimates of time by the use of the resource utilization in dementia (RUD)-instrument
    Anders Wimo
    Aging Research Center ARC, Division of Geriatric Epidemiology and Medicine, Neurotec, Karolinska Institutet, Huddinge Hospital, B84, S 141 86 Stockholm, Sweden
    Arch Gerontol Geriatr 44:71-81. 2007
    ..9). There was a high correlation between interview-based data and register data regarding hospital care, family physician, and district nurse visits. In conclusion, interviews may serve as a valid and reliable substitute for observations...
  5. ncbi request reprint Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL
    Linus Jönsson
    Neurotec, Section for Geriatric Epidemiology, Karolinska Institutet, Stockholm, Sweden
    Alzheimer Dis Assoc Disord 20:49-55. 2006
    ..The study shows that the EuroQoL can be used to rate utilities in Alzheimer disease, but there are important differences between patient- and proxy-ratings...
  6. ncbi request reprint More illness and less disease? A 20-year perspective on chronic disease and medication
    Bertil Hagstrom
    Department of Primary Health Care, Goteborg University, Goteborg, Sweden
    Scand J Public Health 34:584-8. 2006
    ..Aims: To investigate the apprehension in respect of chronic disease among the working population in a Swedish community in 2000 compared with 1980...
  7. ncbi request reprint Societal burden and economics of vascular dementia: preliminary results from a Swedish-population-based study
    Anders Wimo
    Neurotec, Division of Geriatric Epidemiology, Karolinska Institutet, Stockholm, Sweden
    Int Psychogeriatr 15:251-6. 2003
    ..The cost from a societal perspective was 23% higher for patients with VaD compared with patients with Alzheimer's disease ( p = .02)...
  8. ncbi request reprint Impact of donepezil treatment for Alzheimer's disease on caregiver time
    Anders Wimo
    Karolinska Institutet, Huddinge, Sweden
    Curr Med Res Opin 20:1221-5. 2004
    ..To assess the impact of donepezil treatment compared with placebo on caregiver time spent assisting patients with Alzheimer's disease (AD)...
  9. ncbi request reprint The use of angiotensin-converting enzyme inhibitors and other drugs with cardiovascular effects by non-demented and demented elderly with a clinical diagnosis of heart failure. A population-based study of the very old
    Inga Klarin
    Aging Research Center, Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Gavlegatan 16, 113 30, Stockholm, Sweden
    Eur J Clin Pharmacol 62:555-62. 2006
    ..The aim of this study was to investigate drug treatment patterns for heart failure (HF) in the very elderly and, in particular, to determine if angiotensin-converting enzyme inhibitors (ACEIs) were under-used by demented persons...
  10. ncbi request reprint The association of inappropriate drug use with hospitalisation and mortality: a population-based study of the very old
    Inga Klarin
    Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Stockholm, Sweden
    Drugs Aging 22:69-82. 2005
    ..The aim of this study was to explore possible associations of IDU with acute hospitalisation and mortality in an elderly population during 3 years of follow-up...
  11. ncbi request reprint Pharmacoeconomics of mild cognitive impairment
    Anders Wimo
    Division of Geriatric Medicine, Neurotec, Karolinska Institutet, Stockholm, Sweden
    Acta Neurol Scand Suppl 179:94-9. 2003
    ..From the Kungsholmen project in Sweden, there are indications that the postponement between MCI and manifest dementia may result in short-term benefits (a few years) of about SEK50,000 (5300 US dollars)...
  12. ncbi request reprint Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations
    Anders Wimo
    Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Stockholm, Sweden
    Drugs Aging 21:279-95. 2004
    ....
  13. ncbi request reprint A population-based study of drug use in the very old living in a rural district of Sweden, with focus on cardiovascular drug consumption: comparison with an urban cohort
    Inga Klarin
    Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet, Sweden
    Pharmacoepidemiol Drug Saf 12:669-78. 2003
    ..To describe drug use among the elderly, with focus on cardiovascular drugs and regional differences...
  14. ncbi request reprint Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project--a population based study in Sweden
    Gunilla Nordberg
    Aging Research Center ARC, Karolinska Institutet, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:639-48. 2007
    ..The aging of the population has become a worldwide phenomenon. This leads to increased demand for services and with limited resources it is important to find a way to estimate how resources can be match to those with greatest need...
  15. ncbi request reprint Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden
    Frances B Garfield
    Caro Research Institute, Concord, Massachusetts 01742, USA
    Pharmacoeconomics 20:629-37. 2002
    ..Galantamine, a new acetylcholinesterase inhibitor and nicotinic modulator, has proved effective in managing patients with Alzheimer's disease in clinical trials...
  16. ncbi request reprint An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial
    Anders Wimo
    Department of Family Medicine, Umea University, Umea, Sweden
    Dement Geriatr Cogn Disord 15:44-54. 2003
    ....
  17. ncbi request reprint Determinants of costs of care for patients with Alzheimer's disease
    Linus Jönsson
    Division of Geriatric Epidemiology, The Neurotec Department, Karolinska Institutet, Stockholm, Sweden
    Int J Geriatr Psychiatry 21:449-59. 2006
    ..Alzheimer's disease (AD), the most common cause of dementia, is a major cause of disability and care burden in the elderly. This study aims to estimate the costs of formal and informal care and identity determinants of care costs...
  18. ncbi request reprint Time spent on informal and formal care giving for persons with dementia in Sweden
    Anders Wimo
    HC Bergsjö, Box 16, S 820 70 Bergsjö, Sweden
    Health Policy 61:255-68. 2002
    ..Some carers do carry a very heavy 24 h responsibility. This aspect of caring must be addressed by the development of well-targeted respite and relief support programmes...
  19. ncbi request reprint [There is a need to reform dementia care. Resources are not used optimally--time for evidence-based care]
    Jan Marcusson
    Geriatriska kliniken, Universitetssjukhuset i Linköping
    Lakartidningen 103:1022-4, 1027-8. 2006
  20. ncbi request reprint Health utilities in mild cognitive impairment and dementia: a population study in Sweden
    Mattias Ekman
    Stockholm Health Economics, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:649-55. 2007
    ..To collect new primary data on community-based health utilities (time trade-off values) in different stages of mild cognitive impairment and dementia from a general population sample...
  21. ncbi request reprint A longitudinal study integrating population, care and social services data. The Swedish National study on Aging and Care (SNAC)
    Marten Lagergren
    Stockholm Gerontology Research Center, Stockholm, Sweden
    Aging Clin Exp Res 16:158-68. 2004
    ..A large, national, long-term, longitudinal, multi-purpose study has been launched in Sweden--the Swedish National study on Aging and Care (SNAC). The study involves four research centers collecting data in four different areas of Sweden...
  22. ncbi request reprint Clinical and economic outcomes--friend or foe?
    Anders Wimo
    Department of Neurobiology, Care and Society, Karolinska University Hospital, Stockholm, Sweden
    Int Psychogeriatr 19:497-507. 2007
    ..Both dementia-specific and generic quality of life instruments are required. Models are necessary but must be transparent so that the assumptions on which the models are built can be critically analyzed...
  23. ncbi request reprint Older patients awaiting emergency department treatment
    Annica Larsson Kihlgren
    Centre for Nursing Science, Orebro University Hospital, Orebro, Sweden
    Scand J Caring Sci 18:169-76. 2004
    ..The way, in which nursing care was carried out, which in this context is discussed in terms of praxis and poieses, appeared to be of major importance for the older peoples' experiences when visiting the ED...
  24. pmc Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors
    Raj N Kalaria
    Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, UK
    Lancet Neurol 7:812-26. 2008
    ..Dementia costs in developing countries are estimated to be US$73 billion yearly, but care demands social protection, which seems scarce in these regions...